ReviewMolecules (Basel, Switzerland)2021
Microbial Efflux Pump Inhibitors: A Journey around Quinoline and Indole Derivatives.
Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Quorum sensing disruption in Enterobacter spp.: unlocking new therapeutic pathways against multidrug-resistant infections.Antonie van Leeuwenhoek · 2026Review
- Structure-Based Drug Design Targeting the Substrate-Binding Pocket of MexB.The protein journal · 2026Review
- Targeting the AcrAB-TolC efflux pump by small molecules selectively addressing the outer membrane factor TolC.Frontiers in pharmacology · 2026Article
- RND efflux pump inhibitor-like natural products as antibiotic adjuvants against multidrug-resistant gram-negative bacteria: a graded-evidence review.Frontiers in microbiology · 2026Review
- Current Insights into Antibiotic Resistance in UropathogenicAntibiotics (Basel, Switzerland) · 2025Review
- Assessment of the Antimicrobial Activity ofInternational journal of molecular sciences · 2025Article
- NorA Efflux Pump Inhibitors: Expanding SAR Knowledge of Pyrazolo[4,3-c][1,2]benzothiazine 5,5-Dioxide Derivatives.Archiv der Pharmazie · 2025Article
- In Vitro and In Vivo Investigations into the Potential of Quinazoline and Quinoline Derivatives as NorA Efflux Pump Inhibitors Against ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Strategies Proposed for the Treatment ofVeterinary sciences · 2024Review
- A Mini-Review of Anti-Listerial Compounds from Marine Actinobacteria (1990-2023).Antibiotics (Basel, Switzerland) · 2024Review
- Types and Mechanisms of Efflux Pump Systems and the Potential of Efflux Pump Inhibitors in the Restoration of Antimicrobial Susceptibility, with a Special Reference toPathogens (Basel, Switzerland) · 2024Review
- Prenylated isoflavonoids from Fabaceae against the NorA efflux pump in Staphylococcus aureus.Scientific reports · 2023Article
- Synthetic and Semisynthetic Compounds as Antibacterials Targeting Virulence Traits in Resistant Strains: A Narrative Updated Review.Antibiotics (Basel, Switzerland) · 2023Review
- Inhibition ofAntibiotics (Basel, Switzerland) · 2023Article
- Efflux, Signaling and Warfare in a Polymicrobial World.Antibiotics (Basel, Switzerland) · 2023Review
- Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2023Review
- A growing battlefield in the war against biofilm-induced antimicrobial resistance: insights from reviews on antibiotic resistance.Frontiers in cellular and infection microbiology · 2023Review
- New quinoline-based triazole hybrid analogs as effective inhibitors of α-amylase and α-glucosidase: Preparation,Frontiers in chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a complex threat to human health and, to date, it represents a hot topic in drug discovery. The use of non-antibiotic molecules to block resistance mechanisms is a powerful alternative to the identification of new antibiotics. Bacterial efflux pumps exert the early step of AMR development, allowing the bacteria to grow in presence of sub-inhibitory drug concentration and develop more specific resistance mechanisms. Thus, efflux pump inhibitors (EPIs) offer a great opportunity to fight AMR, potentially restoring antibiotic activity. Based on our experience in designing and synthesizing novel EPIs, herein, we retrieved information around quinoline and indole derivatives reported in literature on this topic. Thus, our aim was to collect all data around these promising classes of EPIs in order to delineate a comprehensive structure-activity relationship (SAR) around each core for different microbes. With this review article, we aim to help future research in the field in the discovery of new microbial EPIs with improved activity and a better safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.